United States - English - NLM (National Library of Medicine)

bryant ranch prepack - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 150 mg - irbesartan tablets usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. irbesartan tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (> 300 mg/day) in patients with type 2 diabetes and hypertension. in this population, irbesartan tablets usp reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology , clinical studies ). irbesartan tablets are contraindicated in patients who are hypersensitive to any component of this product. do not coadminister aliskiren with irbesartan tablets in patients with diabetes (see precautions, drug interactions ).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - methylergonovine maleate (unii: ir84jpz1rk) (methylergonovine - unii:w53l6fe61v) - methylergonovine maleate 0.2 mg - following delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. for control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder. hypertension; toxemia; pregnancy; and hypersensitivity. methergine (methylergonovine maleate) has not been associated with drug abuse or dependence of either a physical or psychological nature.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate 100 mg - benzonatate is indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pharmaram ltd - solifenacin succinate - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - clorazepate dipotassium (unii: 63fn7g03xy) (clorazepic acid - unii:d51wo0g0l4) - clorazepate dipotassium tablets, usp are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. clorazepate dipotassium tablets, usp are indicated as adjunctive therapy in the management of partial seizures. the effectiveness of clorazepate dipotassium tablets, usp in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. long-term studies in epileptic patients, however, have shown continued therapeutic activity. the physician should reassess periodically the usefulness of the drug for the individual patient. clorazepate dipotassium tablets, usp are indicated for the symptomatic relief of acute alcohol withdrawal. clorazepate dipotassium tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate (unii: h527kap6l5) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - adderall® is indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least six of the following symptoms must have persisted for a

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - parkinson’s disease ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). restless legs syndrome ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - parkinson’s disease ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). restless legs syndrome ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride tablets usp are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride tablets usp are not indicated in the management of hypertensive emergencies. propranolol hydrochloride tablets usp are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride tablets usp are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. propranolol hydrochloride tablets usp are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. propranolol hydrochloride tablets usp are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not in